Moreover, these levels strongly correlated with tau, a marker of axonal degeneration, suggesting CHI3L1’s potential as a surrogate marker for disease progression [29, 157].Peripheral blood studies also revealed significantly higher plasma CHI3L1 levels in CJD patients compared to individuals with other neurodegenerative dementias, neurologic controls, and healthy individuals [37, 79]. This evidence concerns the gene CHI3L1 and Creutzfeldt Jacob disease.